Case History: Chantix™/Champix™ (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid

被引：21
|
作者：
Coe, Jotham W. [1 ]
Rollema, Hans [1 ]
O'Neill, Brian T. [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44 | 2009年 / 44卷
关键词：
RANDOMIZED CONTROLLED-TRIAL; 10-SUBSTITUTED CYTISINE DERIVATIVES; SUSTAINED-RELEASE BUPROPION; DISCRIMINATIVE STIMULUS; DOSE PHARMACOKINETICS; CHOLINERGIC-RECEPTOR; HEALTHY SMOKERS; BETA-2; SUBUNIT; IN-VIVO; (-)-CYTISINE;
D O I：
10.1016/S0065-7743(09)04404-2
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
[No abstract available]
引用
收藏
页码：71 / +
页数：32
相关论文
共 50 条
  • [11] EFFICACY OF VARENICLINE, AN NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, VS PLACEBO FOR SMOKING CESSATION. A RANDOMIZED CONTROLLED TRIAL
    Wiratmoko, Mirsyam R.
    Yunus, Faisal
    Susanto, Agus D.
    Ginting, Tribowo T.
    Kekalih, Aria
    RESPIROLOGY, 2013, 18 : 66 - 66
  • [12] Safety and Tolerability of Varenicline Tartrate (Champix®/Chantix®) for Smoking Cessation in HIV-Infected Subjects: A Pilot Open-Label Study
    Cui, Qu
    Robinson, Linda
    Elston, Dawn
    Smaill, Fiona
    Cohen, Jeffrey
    Quan, Corinna
    McFarland, Nancy
    Thabane, Lehana
    McIvor, Andrew
    Zeidler, Johannes
    Smieja, Marek
    AIDS PATIENT CARE AND STDS, 2012, 26 (01) : 12 - 19
  • [13] Pharmacology of varenicline, a clinically effective alpha4beta2 nicotinic acetylcholine receptor partial agonist for smoking cessation
    Rollema, Hans
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S19 - S19
  • [14] Smoking cessation aid varenicline: effect on the expression of neuronal nicotinic acetylcholine receptors
    Both, C.
    Kaiser, C.
    Birke, J.
    Lange-Asschenfeldt, C.
    Kojda, G.
    EUROPEAN HEART JOURNAL, 2011, 32 : 380 - 381
  • [15] The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review
    Crunelle, Cleo L.
    Miller, Michelle L.
    Booij, Jan
    van den Brink, Wim
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 (02) : 69 - 79
  • [16] Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial
    Gonzales, David
    Rennard, Stephen I.
    Nides, Mitchell
    Oncken, Cheryl
    Azoulay, Salomon
    Billing, Clare B.
    Watsky, Eric J.
    Gong, Jason
    Williams, Kathryn E.
    Reeves, Karen R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 47 - 55
  • [17] Varenicline - An oral partial nicotine agonist for smoking cessation
    Feret, Brett
    Orr, Kelly
    FORMULARY, 2006, 41 (06) : 265 - +
  • [18] Award Address (ACS Award for Creative Invention sponsored by ACS Corporation Associates). Discovery of Chantix (varenicline tartrate), an aid to smoking cessation
    Coe, Jotham
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [19] Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial
    Jorenby, Douglas E.
    Hays, J. Taylor
    Rigotti, Nancy A.
    Azoulay, Salomon
    Watsky, Eric J.
    Williams, Kathryn E.
    Billing, Clare B.
    Gong, Jason
    Reeves, Karen R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 56 - 63
  • [20] A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
    Tsai, Shih-Tzu
    Cho, Hong-Jun
    Cheng, Huey-Shinn
    Kim, Cheol-Hwan
    Hsueh, Kuang-Chieh
    Billing, Clare B., Jr.
    Williams, Kathryn E.
    CLINICAL THERAPEUTICS, 2007, 29 (06) : 1027 - 1039
12345